Cardiovascular side effects of psychopharmacologic therapy

Potočnjak, Ines; Degoricija, Vesna; Baudoin, Dina Vukičević; Čulig, Josip; Jakovljević, Miro

doi:10.1016/j.ijcard.2016.06.057

Cited by 8 publications

(4 citation statements)

References 55 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Perhaps it is time to give tPBM serious trials for these indications considering its established safety and notable lack of adverse effects, and relative cost-effective nature? Although psychiatric drugs such as anti-depressants are well established and among some of the world’s biggest selling pharmaceuticals, their rate of effectiveness is disappointing and they can have high rates of distressing side-effects [108, 109]. Although the testing of tPBM for depression has a lot further to go, the availability of inexpensive home-use LED devices suggests that tPBM could also be used for this indication.…”

Section: Future Outlookmentioning

confidence: 99%

Photobiomodulation and the brain: a new paradigm

Hennessy¹,

Hamblin

2016

J. Opt.

171

117

View full text Add to dashboard Cite

Transcranial photobiomodulation (PBM) also known as low level laser therapy (tLLLT) relies on the use of red/NIR light to stimulate, preserve and regenerate cells and tissues. The mechanism of action involves photon absorption in the mitochondria (cytochrome c oxidase), and ion channels in cells leading to activation of signaling pathways, up-regulation of transcription factors, and increased expression of protective genes. We have studied PBM for treating traumatic brain injury (TBI) in mice using a NIR laser spot delivered to the head. Mice had improved memory and learning, increased neuroprogenitor cells in the dentate gyrus and subventricular zone, increased BDNF and more synaptogenesis in the cortex. These highly beneficial effects on the brain suggest that the applications of tLLLT are much broader than at first conceived. Other groups have studied stroke (animal models and clinical trials), Alzheimer’s disease, Parkinson’s disease, depression, and cognitive enhancement in healthy subjects.

show abstract

Section: Future Outlookmentioning

confidence: 99%

Photobiomodulation and the brain: a new paradigm

Hennessy¹,

Hamblin

2016

J. Opt.

171

117

View full text Add to dashboard Cite

show abstract

“…Neuroleptic (antipsychotic) cardiomyopathy (NCMP) is a little known to a wide range of doctors iatrogenic pathology. It is associated with a side cardiotoxic effect of antipsychotic drugs [1][2][3][4][5][6][7][8][9]. The disease belongs to secondary specific metabolic dilated cardiomyopathies [10][11][12] and is characterized by diffusion damage of a myocardium, by sharp decrease in its contractile function and by the progressing of congestive chronic heart failure (CHF) [8,10,11,[13][14][15][16][17].…”

Section: Upine Publishersmentioning

confidence: 99%

Neuroleptic Cardiomyopathy: Let’s Get Acquainted

Vp¹

2018

LOJMS

View full text Add to dashboard Cite

“…The current treatment for psychiatric disorders relies on medications such as chlorpromazine, perphenazine, haloperidol, clozapine, risperidone, tricyclic antidepressants, mood stabilizers, and others [8] . The current treatment for psychiatric disorders relies on medications such as chlorpromazine, perphenazine, haloperidol, clozapine, risperidone, tricyclic antidepressants, mood stabilizers, and other [9][10][11][12][13] . As a result, the quality of life for patients with psychiatric disorders remains unsatisfactory despite aggressive medication.…”

Section: Introductionmentioning

confidence: 99%

Exploring the causal relationship between BMI and psychiatric disorders using two-sample Mendelian randomization

ZHANG,

Zou,

Wang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background The study aimed to assess the causal relationship using two-sample Mendelian randomization analyses of BMI and five classic psychiatric disorders (depression, bipolar disorder, schizophrenia, autism, and anxiety disorder) in sequence. Methods Data related to BMI, depression, bipolar disorder, schizophrenia, autism, and anxiety disorders were downloaded from the GWAS database, and based on the genetic variation associated with each data were analyzed by utilizing five methods: MR Egger, Weighted median, Inverse variance weighted, Simple mode, Weighted mode, and five methods, while Mendelian randomization analysis between two samples was performed. Results Under IVW analysis, a positive causal relationship was found between BMI and depression (OR: 1.009, 95% CI: 1.002–1.016, P = 0.009) as well as bipolar disorder (OR: 1.001, 95% CI: 1.001–1.002, P = 0.002). Additionally, a negative causal relationship was found between BMI and schizophrenia (OR: 0.702, 95% CI: 0.560–0.881, P = 0.002). However, no causal relationship was found between BMI and autism (OR: 1.114, 95% CI: 0.972–1.278, P = 0.120) or anxiety disorders (OR: 1.000, 95% CI: 0.998–1.001, P = 0.630). Conclusion A causal relationship between BMI in depression, bipolar disorder, and schizophrenia. Maintaining BMI within the range of normal indicators is important not only for physical health care, but also for the prevention of psychiatric disorders.

show abstract

Cardiovascular side effects of psychopharmacologic therapy

Cited by 8 publications

References 55 publications

Photobiomodulation and the brain: a new paradigm

Photobiomodulation and the brain: a new paradigm

Neuroleptic Cardiomyopathy: Let’s Get Acquainted

Exploring the causal relationship between BMI and psychiatric disorders using two-sample Mendelian randomization

Contact Info

Product

Resources

About